伊马替尼药代动力学相关的基因多态性研究进展  

Advances in gene polymorphisms related to pharmacokinetics of imatinib

作　　者：曾晶[1,2] 徐萍[1,2] 姜志平[3] 

机构地区：[1]中南大学湘雅二医院药学部,长沙410011 [2]中南大学临床药学研究所,长沙410011 [3]中南大学湘雅医院血液科,长沙410008

出　　处：《中国临床药理学杂志》2017年第2期185-188,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：伊马替尼是治疗慢性粒细胞白血病(CML)的一线药物,具有选择性高、疗效显著的特点。但在临床上,不同患者间临床效应存在明显个体差异。近年来,有关伊马替尼相关代谢酶或转运体基因多态性的研究已成为热点,但研究结果存在差异。因此,本文重点关注与伊马替尼药代动力学相关的基因多态性研究,并对其做一综述,以期为伊马替尼临床个体化治疗提供一定参考依据。Imatinib is the first line treatment of chronic myelocytic leukemia（ CML） and has high selectivity and efficacy. However,clinical effects of this medicine show large interpatient variability. In recent years,enzyme and transporter polymorphisms are research focus for imatinib. But different researches have various results. Therefore, we focused on influence of polymorphisms on pharmacokinetics of imatinb and summarized relevant literatures so as to provide references for clinical individualized treatment.

关 键 词：伊马替尼 基因多态性 药代动力学 

分 类 号：R973[医药卫生—药品]